Sun Sep 15 14:46:51 UTC 2024: ## Institutional Investors Show Continued Confidence in Edwards Lifesciences (EW)

**Irvine, California – September 15, 2024** – Edwards Lifesciences Co. (NYSE:EW), a leading medical research company specializing in structural heart disease and critical care monitoring, saw increased interest from institutional investors in the second quarter of 2024. Meeder Advisory Services Inc. raised its position in the company by 39.5%, acquiring an additional 2,813 shares, bringing their total holdings to 9,933 shares worth $918,000.

Several other major players also adjusted their positions in EW:

* Vanguard Group Inc. boosted its stake by 1.1% in the first quarter, owning 52,964,394 shares valued at $5,061,277,000.
* Bank of New York Mellon Corp increased its holdings by 4.3% in the second quarter, now owning 19,782,909 shares worth $1,827,347,000.
* Wellington Management Group LLP lifted its position by 2.4% in the fourth quarter, owning 16,827,510 shares worth $1,283,098,000.
* Norges Bank acquired a new stake in the fourth quarter valued at $648,540,000.
* Price T Rowe Associates Inc. MD expanded its holdings by 57.9% in the first quarter, now owning 6,516,260 shares worth $622,695,000.

These moves highlight the ongoing confidence in Edwards Lifesciences, with institutional investors owning 79.46% of the company’s stock.

While several brokerages recently lowered their price targets, the overall sentiment remains positive, with 11 analysts issuing “buy” ratings and 15 issuing “hold” ratings. The company currently holds an average rating of “Hold” with an average price target of $80.29.

Edwards Lifesciences recently reported strong second-quarter earnings, exceeding analysts’ expectations with earnings per share of $0.70 and revenue of $1.63 billion. This performance further reinforces investor confidence in the company’s growth trajectory.

However, recent insider trading activity saw the sale of 16,250 shares worth $1,218,138, potentially indicating some caution from within the company.

Despite these mixed signals, Edwards Lifesciences remains a prominent player in the medical research industry, poised to capitalize on the growing demand for innovative heart disease and critical care solutions. Investors and analysts will be closely watching the company’s performance in the coming quarters to gauge its long-term prospects.

Read More